SCHEMBL6683129

SCHEMBL6683129

CC(C)C(C(F)(F)F)C(F)(F)F

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14297644 0.93
SCHEMBL15491271 0.93
SCHEMBL14146867 0.83
SCHEMBL10092703 0.82
SCHEMBL17729865 0.79
SCHEMBL18791640 0.77
SCHEMBL23416780 0.77
SCHEMBL20033681 0.77
SCHEMBL20436104 0.74
SCHEMBL4654337 0.73 ALDH1A1 (0.36) ALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5275669-A Degreasing glass, metal, plastic and fiber surfaces ALLIEDSIGNAL INC. (US) 1994-01-04 US claimed
US-20240217930-A1 SARS-COV-2 MPRO INHIBITOR COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2024-07-04 US disclosed
US-11860536-B2 Three-dimensional crosslinker composition and method of manufacturing electronic devices using the same UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) 2024-01-02 US disclosed
US-11787794-B2 Aminothiazole compounds and methods using same TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-10-17 US disclosed
EP-3743430-B1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 EP disclosed
US-20230234929-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
US-11700765-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-07-11 US disclosed
US-20230200214-A1 COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF DUK SAN NEOLUX CO., LTD. (KR) 2023-06-22 US disclosed
US-20230135758-A1 ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF UNIV CALIFORNIA (US) 2023-05-04 US disclosed
US-20090226382-A1 HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME LIVING PROOF, INC. (US) 2009-09-10 US disclosed
US-20090191141-A1 HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME LIVING PROOF, INC. (US) 2009-07-30 US disclosed
US-20090104136-A1 HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME LIVING PROOF, INC. 2009-04-23 US disclosed
WO-2009003999-A2 CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-01-08 WO disclosed
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-07-12 US disclosed
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-07-12 US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed
WO-2007062314-A2 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 WO disclosed
EP-1193309-B1 Solvent blend for use in high purity precursor removal AIR PROD & CHEM (US) 2004-11-03 EP disclosed
EP-1193309-A1 Solvent blend for use in high purity precursor removal AIR PRODUCTS AND CHEMICALS, INC. (US) 2002-04-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217930-A1 SARS-COV-2 MPRO INHIBITOR COMPOUNDS ACE2, SARS1, ACE ALDH1A1 2710/4885TSHR 1683/4885HSD17B10 1257/4885
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 ALDH1A1 2353/4885TSHR 2250/4885HSD17B10 255/4885
US-20230200214-A1 COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF EMC1, EMC2, EPCAM ALDH1A1 969/4885TSHR 3804/4885HSD17B10 3064/4885
US-11787794-B2 Aminothiazole compounds and methods using same BRCA1, ALDH7A1, MGMT ALDH1A1 116/4885TSHR 4231/4885HSD17B10 560/4885
US-20090226382-A1 HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME TET1, TET2, TET3 ALDH1A1 457/4885TSHR 3749/4885HSD17B10 221/4885
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 ALDH1A1 2353/4885TSHR 2250/4885HSD17B10 255/4885
US-11860536-B2 Three-dimensional crosslinker composition and method of manufacturing electronic devices using the same BMI1, SETDB1, EED ALDH1A1 149/4885TSHR 4526/4885HSD17B10 1163/4885
US-20090104136-A1 HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME TET1, TET2, TET3 ALDH1A1 457/4885TSHR 3749/4885HSD17B10 221/4885
US-20230234929-A1 RAS INHIBITORS KRAS, NRAS, HRAS ALDH1A1 4437/4885TSHR 3332/4885HSD17B10 4458/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR ALDH1A1 4528/4885TSHR 4120/4885HSD17B10 4436/4885
US-20090191141-A1 HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME TET1, TET2, TET3 ALDH1A1 457/4885TSHR 3749/4885HSD17B10 221/4885
US-20230135758-A1 ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF EEF1A1, EEF1B2, EEF1G ALDH1A1 3486/4885TSHR 4402/4885HSD17B10 2980/4885
US-11700765-B2 Organic electroluminescent materials and devices SOD1, L1CAM, MCM2 ALDH1A1 445/4885TSHR 4446/4885HSD17B10 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.